Victoza（肥満治療薬）：市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16
4 Disease Management 17
4.1 Treatment Overview 17
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 27
6 Opportunity and Unmet Need 29
6.1 Overview 29
6.2 A Drug with Greater Than 10% Average Weight Loss 30
6.2.1 Unmet Need 30
6.2.2 Gap Analysis 31
6.2.3 Opportunity 32
6.3 A Drug with Increased Safety and Tolerability 32
6.3.1 Unmet Need 32
6.3.2 Gap Analysis 33
6.3.3 Opportunity 33
6.4 Reimbursement by Private and Public Payers 33
6.4.1 Unmet Need 33
6.4.2 Gap Analysis 35
6.4.3 Opportunity 35
6.5 Increased Physician Education 35
6.5.1 Unmet Need 35
6.5.2 Gap Analysis 36
6.5.3 Opportunity 36
6.6 Increased Drug-Treatment Rate 37
6.6.1 Unmet Need 37
6.6.2 Gap Analysis 37
6.6.3 Opportunity 38
6.7 Improved Guidelines 38
6.7.1 Unmet Need 38
6.7.2 Gap Analysis 39
6.7.3 Opportunity 39
6.8 Improved Approach to Diagnosis 39
6.8.1 Unmet Need 39
6.8.2 Gap Analysis 40
6.8.3 Opportunity 40
7 Pipeline Assessment 41
7.1 Overview 41
7.2 Promising Drugs in Clinical Development 44
8 Victoza (liraglutide) 47
8.1 Overview 47
8.2 Efficacy 48
8.3 Safety 50
8.4 Dosing and Formulation 50
8.5 Potential Clinical Positioning 51
8.6 Potential Commercial Positioning 51
8.7 Pricing and Reimbursement 51
8.8 SWOT Analysis 52
8.9 Forecast 52
9 Appendix 54
9.1 Bibliography 54
9.2 Abbreviations 59
9.3 Research Methodology 60
9.4 Forecasting Methodology 60
9.4.1 Percent Drug-Treated Obesity Patients 61
9.4.2 Key Launch Dates 61
9.4.3 Individual Drug Assumptions 62
9.4.4 Generic Erosion 62
9.5 Physicians, Specialists, and Payers Included in This Study 63
9.6 About the Authors 66
9.6.1 Analysts 66
9.6.2 Therapy Director – CVMD and Infectious Disease 67
9.6.3 Director – Medical Devices 67
9.6.4 Global Head of Healthcare 68
9.7 About GlobalData 69
9.8 Disclaimer 69